Fundraising Fox

Iantrek

Elkins Park, US · Founded 2019 · Delaware corporation · 6 known investors

iantrekmed.com ↗

Iantrek develops medical devices and technologies for micro-interventional ophthalmic surgery, specifically targeting glaucoma treatment through uveoscleral pathway outflow enhancement for surgeons and ophthalmologists.

BiotechMedical Devicesin /iantrek-inc

Founders & leadership

TI
Tsontcho IanchulevExecutive Officer, Director
MH
Michael HaydinExecutive Officer
AC
Andrew CorleyDirector
SB
Stephen BlochDirector
JK
Jeffry K WeinhuffDirector
FT
Farrell TysonDirector
RW
Robert WeinrebDirector
MM
Marc-Andre MarcotteDirector
JM
James MazzoDirector

Investors · 6

aMoonRa'anana
Civilization Ventures Management, LlcTiburon · $1M – $10M
FemHealth VenturesShort Hills
JSD Capital, LLCNew York · $10Mvia Jordan S. Davis · inferred
US Venture PartnersMenlo Park · $500K – $10Mvia Casey Tansey · board
Visionary VenturesNewport Beach · $5M – $15M

Reported raises · per SEC filings

Form D private placements
▶$34.7MraisedAug 2025 · 21 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Tsontcho IanchulevExecutive Officer, Director
  • Todd SoneDirector
  • James MazzoDirector
  • Adam SzaronosExecutive Officer, Director
  • Casey TanseyDirector
  • Robert WeinrebDirector
  • Marc-Andre MarcotteDirector
  • Jeffry K. WeinhuffDirector
  • Michael HaydinExecutive Officer
  • Farrell TysonDirector
Offering amount
$42M
Amount sold
$34.7M
First sale
Aug 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.8MraisedFeb 2025 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Michael HaydinExecutive Officer
  • Robert WeinrebDirector
  • Tsontcho IanchulevExecutive Officer, Director
  • Marc-Andre MarcotteDirector
  • Jeffry K WeinhuffDirector
  • Farrell TysonDirector
  • James MazzoDirector
Offering amount
$5.5M
Amount sold
$2.8M
First sale
Feb 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$15.4MraisedAug 2022 · 25 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Michael George Haydin, IVExecutive Officer
  • James MazzoDirector
  • Jeffrey K. WeinhuffDirector
  • Farrell TysonDirector
  • Tsontcho IanchulevExecutive Officer, Director
  • Marc-Andre MarcotteDirector
  • Robert WeinrebDirector
Offering amount
$25M
Amount sold
$15.4M
First sale
Aug 2022
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5.2MraisedOct 2020 · 29 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Robert WeinrebDirector
  • James MazzoDirector
  • Jeffry K WeinhuffDirector
  • Andrew CorleyDirector
  • Tsontcho IanchulevExecutive Officer, Director
  • Stephen BlochDirector
  • Michael HaydinExecutive Officer
Offering amount
$5.2M
Amount sold
$5.2M
First sale
Oct 2020
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news